| COMPANY |
Annovis Bio, Inc. |
| COURT |
United States District Court for the Eastern District of Pennsylvania |
| CASE NUMBER |
21-cv-03668 |
| JUDGE |
The Honorable Lee Albert |
| CLASS PERIOD |
May 21, 2021 and July 28, 2021 |
| SECURITY TYPE |
Common Stock |
Case Background:
The Class Period commences on May 21, 2021, when Annovis issued a press release entitled “Annovis Bio Announces Positive Phase 2 Data – ANVS401 Improves Cognition in Alzheimer’s Disease – Patients’ Cognition Improved 3.3 Points on ADAS-Cog11.” Then, on June 1, 2021, Annovis issued a press release entitled “Annovis Bio’s ANVS401 Improves Speed and Accuracy in Alzheimer’s and in Parkinson’s Patients.”
The complaint alleges that throughout the Class Period, the Defendants failed to disclose to investors that: (1) Annovis’s ANVS401 did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, the defendants’ positive statements about Annovis’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Current Status of Case:
On October 12, 2021, Lead Plaintiff filed a Motion for Voluntary Dismissal. This action has concluded.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.